If you know either of us, you know neither of us would pass up a chance to say, “I told you so.” As we looked ahead to 2024 in January, we speculated that psychedelics could be legalized as a ...

-A single oral administration of MM120 100 µg met its key secondary endpoint and maintained a clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with a 65% ...

- Panorama is the second Phase 3 trial of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for ...

Add Yahoo as a preferred source to see more of our stories on Google. For decades, scientists have argued there are potential health benefits to LSD. Silas Stein/dpa A 100 microgram dose of a ...

NEW YORK, April 15, 2025--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product ...

Add Yahoo as a preferred source to see more of our stories on Google. March 7 (UPI) --A psychedelic medicine biotech company announced Thursday its LSD-based drug has won U.S. Food and Drug ...

We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. Mind Medicine (MindMed) Inc. stands fourth among them. Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), a clinical-stage ...

Encouraging outcomes from a clinical study on the LSD-analog substance MM120, or lysergide d-tartrate, have led the Food and Drug Administration (FDA) to designate it as a “breakthrough therapy” for ...

After more than a decade without major breakthroughs in anxiety medication, several promising treatments are now moving through clinical trials. These investigational options use new delivery systems, ...

A trial explored the effect of MM120, a new pharmaceutically optimised dissolvable LSD tablet, on patients with generalised anxiety disorder. A trial explored the effect of MM120, a new ...